These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 1699658

  • 1. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients.
    Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG, Finkelstein J, Reaman G, Hammond GD, Holcenberg JS.
    Cancer Res; 1990 Nov 15; 50(22):7226-31. PubMed ID: 1699658
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK.
    Clin Cancer Res; 1998 Jan 15; 4(1):45-52. PubMed ID: 9516951
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
    Leiby JM, Snider KM, Kraut EH, Metz EN, Malspeis L, Grever MR.
    Cancer Res; 1987 May 15; 47(10):2719-22. PubMed ID: 2436757
    [Abstract] [Full Text] [Related]

  • 4. Phase I clinical trials with fludarabine phosphate.
    Von Hoff DD.
    Semin Oncol; 1990 Oct 15; 17(5 Suppl 8):33-8. PubMed ID: 1699281
    [Abstract] [Full Text] [Related]

  • 5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Malspeis L, Grever MR, Staubus AE, Young D.
    Semin Oncol; 1990 Oct 15; 17(5 Suppl 8):18-32. PubMed ID: 1699279
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
    Leiby JM, Grever MR, Staubus AE, Neidhart JA, Malspeis L.
    J Natl Cancer Inst; 1988 May 18; 80(6):447-9. PubMed ID: 2452888
    [Abstract] [Full Text] [Related]

  • 10. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M.
    Leukemia; 1987 Sep 18; 1(9):638-43. PubMed ID: 3478543
    [Abstract] [Full Text] [Related]

  • 11. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.
    Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW.
    Cancer Res; 1986 Nov 18; 46(11):5953-8. PubMed ID: 2428488
    [Abstract] [Full Text] [Related]

  • 12. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.
    Warrell RP, Berman E.
    J Clin Oncol; 1986 Jan 18; 4(1):74-9. PubMed ID: 2416889
    [Abstract] [Full Text] [Related]

  • 13. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 18; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
    Arima N, Mizoguchi H, Shirakawa S, Tomonaga M, Takatsuki K, Ohno R.
    Gan To Kagaku Ryoho; 1999 Apr 18; 26(5):619-29. PubMed ID: 10234292
    [Abstract] [Full Text] [Related]

  • 17. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov 18; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 18. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
    Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clark G.
    Cancer Res; 1984 Sep 18; 44(9):4183-6. PubMed ID: 6204752
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 18; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.